Navigation Links
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
Date:11/15/2011

CRANBURY, N.J., Nov. 15, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its first quarter ended September 30, 2011. Palatin reported a net loss of $3.4 million, or $(0.10) per basic and diluted share, for the quarter ended September 30, 2011, compared to a net loss of $4.6 million, or $(0.39) per basic and diluted share, for the same period in 2010.

The decrease in net loss for the quarter ended September 30, 2011, compared to the same period last fiscal year, is the result of Palatin's previously announced strategic decision to reduce staffing levels and to focus resources and efforts on clinical trials of bremelanotide and preclinical development of an inhaled formula of PL-3994 and a new peptide drug candidate for sexual dysfunction.  The decrease in net loss per share was also significantly impacted by the higher number of shares outstanding in the quarter ended September 30, 2011 compared to the same period last fiscal year due primarily to the sale of shares of stock in March 2011.

REVENUERevenues for the quarter ended September 30, 2011 were $27,000, compared to $216,000 for the same period in 2010, reflecting the decrease in revenue recognized under Palatin's agreements with AstraZeneca AB.

COSTS AND EXPENSESTotal operating expenses for the quarter ended September 30, 2011 were $3.4 million, compared to $4.8 million for the comparable quarter of 2010. The decrease in operating expenses for the quarter is the result of Palatin's previously announced strategic decision to reduce staffing levels and to focus resources and efforts on clinical trials of bremelanotide and PL-3994 and preclinical development of an inhaled formul
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2014)... Until recently, pets suffering from arthritic ailments ... their pain. Pill therapies are costly, can be harmful ... , The procedure uses adult (not embryonic) animal ... regenerative healing power. MediVet's equipment enable veterinarians to remove ... stem cells, then activate and inject the cells into ...
(Date:9/11/2014)... 11, 2014  Ikonopedia will showcase its new ... imaging reporting modules here at the Intensive Breast ... Ikonopedia,s revolutionary suite of report generation software tools ... they look like rather than what they are ... reporting efficiency, and optimize facility operations.  ...
(Date:9/11/2014)... Florida (PRWEB) September 11, 2014 Central ... to announce his partnerships with several Brevard County animal ... Dr. Christiansen has been working in the area since ... small animals since 2008, and is happy to now ... the years Dr. Christiansen has used stem cell therapy ...
(Date:9/10/2014)... Jersey (PRWEB) September 11, 2014 ... its annual Innovations in Dermatological Sciences conference Oct. ... focus on how the university, industry and government ... into clinical use. , This conference is unique ... with cross-sector collaboration, to share their successes, best-practices, ...
Breaking Biology Technology:MediVet America Secures Exclusive Worldwide License with Nanofiber Veterinary 2Ikonopedia Showcases New MQSA Management System and Reporting Modules at Intensive Breast Ultrasound Meeting 2Ikonopedia Showcases New MQSA Management System and Reporting Modules at Intensive Breast Ultrasound Meeting 3Dr. Jeff Christiansen is Now Offering Stem Cell Therapy for Pets at Five Brevard County Animal Hospitals and Beyond 2Dr. Jeff Christiansen is Now Offering Stem Cell Therapy for Pets at Five Brevard County Animal Hospitals and Beyond 3Innovations in Dermatological Sciences 2014 2Innovations in Dermatological Sciences 2014 3
... Five exceptional oncology nurses out of nearly 2,400 ... | US Oncology for their dedication to their ... Oncology Nursing Award honors those nurses in the United ... determination in providing the highest quality oncology nursing care to ...
... 22, 2011 The founders of Oncobiologics, Inc. today ... services, will launch itself to the biopharmaceutical industry at ... held June 27-30 at the Walter E. Washington Convention ... by a group of leading scientists and engineers from ...
... features below 100 nanometres have numerous applications ranging ... Tecnalia participates in a intragated FP7 European Project ... on nanoimprinting techniques (NIL), as a core aspect ... benefits followed are cost reduction, simpler fabrication process ...
Cached Biology Technology:McKesson Specialty Care Solutions | US Oncology Honors Five Exceptional Oncology Nurses for Outstanding Work 2McKesson Specialty Care Solutions | US Oncology Honors Five Exceptional Oncology Nurses for Outstanding Work 3McKesson Specialty Care Solutions | US Oncology Honors Five Exceptional Oncology Nurses for Outstanding Work 4Oncobiologics, Inc. to Unveil New Biologics Proof-of-Concept Engine at BIO International Convention 2
(Date:9/12/2014)... Melbourne researchers have discovered that cartilage plays an ... joints seen in rheumatoid arthritis, rather than being ... Tommy Liu, Professor Ian Wicks, Dr Kate Lawler, ... and Eliza Hall Institute made the discovery while ... controlling inflammation during rheumatoid arthritis. The study was ...
(Date:9/12/2014)... Washington , September 12, 2014 ... source covering leading sectors including biometrics and mobile tech, issues ... launch of Apple Pay, its new payment service. ... founder of the Secure Identity and Biometrics Association (SIBA) and ... NXTD ) a company that is introducing its own ...
(Date:9/11/2014)... deadly legacy of DDT, American peregrine falcons ( Falco ... biologists proposed to stop rearing young birds in captivity ... Doug Bell published models that year in ESA,s journal ... for the falcon in California, with and without direct ... that the birds would continue to recover without captive ...
Breaking Biology News(10 mins):No innocent bystander: Cartilage contributes to arthritis 2Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 2Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 3Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 4Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 5Volunteer 'eyes on the skies' track peregrine falcon recovery in California 2Volunteer 'eyes on the skies' track peregrine falcon recovery in California 3Volunteer 'eyes on the skies' track peregrine falcon recovery in California 4Volunteer 'eyes on the skies' track peregrine falcon recovery in California 5
... in the fruitfly genome, Johns Hopkins scientists have identified those ... captured a global view of all the genes turned on ... to be published April 3 in Developmental Cell, has implications ... move similarly to spread beyond an original tumor, which are ...
... Italy and Virginia Tech in the United States have ... for the production xanthurenic acid (XA) in Anopheles gambiae, ... in the sexual reproduction of the malaria parasite (Plasmodium ... of XA could be an avenue for development of ...
... from a new, five-year study show that regular use of ... cancer by up to 71 percent and may offer similar ... , The study findings were released today at the ... Washington, D.C. , "We believe this is the first ...
Cached Biology News:Researchers identify genes in fruitflies that may shed light on human cancer spread 2Oxidation defense in mosquitoes benefits malaria parasite 2COX-2 inhibitors significantly reduce risk of cancer 2
Anti-Indolamine (Indoleamine) 2,3-dioxygenase Immunogen: Recombinant human IDO. Available Date: 38454...
Anti-Ephrin B1 Host: rabbit polyclonal Species Reactivity: human Applications: WB Storage: 4C...
Human Regulatory T cell Staining Kit #2 (w/ APC Foxp3 PCH101, FITC CD4, PE CD25)...
...
Biology Products: